Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

161.61 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT
From Natera, Inc.
Via Business Wire
Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
From Natera, Inc.
Via Business Wire
Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows
From Natera, Inc.
Via Business Wire
How Do Investors Really Feel About Natera?
 
Via Benzinga
2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Stocks making big moves yesterday: Acadia Healthcare, Tesla, THOR Industries, Natera, and P10
Check out the companies making headlines yesterday: 
Via StockStory
Topics Electric Vehicles
Here's How Much $1000 Invested In Natera 5 Years Ago Would Be Worth Today
 
Via Benzinga
Why Natera (NTRA) Stock Is Down Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 4.5% in the afternoon session after Wells Fargo & Company initiated coverage on the stock with a neutral "equal weight" rating and set a... 
Via StockStory
Topics Artificial Intelligence Lawsuit
Deep Dive Into Natera Stock: Analyst Perspectives (6 Ratings)
 
Via Benzinga
If You Invested $100 In Natera Stock 5 Years Ago, You Would Have This Much Today
 
Via Benzinga
2 Unprofitable Stocks on Our Watchlist and 1 We Ignore
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
Why Natera (NTRA) Stock Is Trading Lower Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 2.7% in the afternoon session after the company reached an $8.25 million settlement in a legal case. The case, titled 'Amanda Davis v.... 
Via StockStory
Topics Artificial Intelligence Lawsuit
Why Natera (NTRA) Shares Are Falling Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 4.1% in the afternoon session after a key competitor, Exact Sciences, announced the launch of a new multi-cancer early detection blood... 
Via StockStory
Topics Intellectual Property
3 Reasons We’re Fans of Natera (NTRA)
Since September 2020, the S&P 500 has delivered a total return of 94.8%. But one standout stock has doubled the market - over the past five years, Natera has surged 186% to $176.64 per share. Its... 
Via StockStory
Topics Stocks
1 Cash-Producing Stock to Own for Decades and 2 We Find Risky
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Topics Supply Chain
Why Natera (NTRA) Stock Is Down Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 0.9% in the morning session after the company announced an unfavorable court ruling in its ongoing patent litigation with competitor... 
Via StockStory
Topics Intellectual Property
NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims
NeoGenomics wins a North Carolina court ruling invalidating key Natera patents, clearing the way for its RaDaR ST assay and boosting investor sentiment. 
Via Benzinga
Topics Intellectual Property
Natera Provides Update on Patent Litigation with NeoGenomics
From Natera, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why Natera (NTRA) Stock Is Up Today
Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 3% in the afternoon session after the company announced its Signatera molecular residual disease test was selected for a Phase III... 
Via StockStory
Topics Earnings
Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer
From Natera, Inc.
Via Business Wire
2 Cash-Heavy Stocks Worth Investigating and 1 We Ignore
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer
From Natera, Inc.
Via Business Wire
Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
From Natera, Inc.
Via Business Wire
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
From Natera, Inc.
Via Business Wire
1 Healthcare Stock to Own for Decades and 2 We Find Risky
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Retirement Stocks
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
From Natera, Inc.
Via Business Wire
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
NTRA Q2 Deep Dive: Oncology Growth, Product Innovation, and Margin Pressures
Genetic testing company Natera (NASDAQ:NTRA). reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 32.2% year on year to $546.6 million. The company’s full-year revenue... 
Via StockStory
Topics Artificial Intelligence
2 Mid-Cap Stocks on Our Watchlist and 1 We Brush Off
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.